Our findings suggest that there is a wide window in human melanomas between the typical ERK signaling flux set by the negative feedback mechanisms and the oncogene-driven maximal ERK pathway capacity that could be exploited therapeutically. This evidence concerns the gene MAPK1 and melanoma.